JPMorgan Chase & Co. Raises Qiagen (NYSE:QGEN) Price Target to $54.00

Qiagen (NYSE:QGEN) had its price objective upped by investment analysts at JPMorgan Chase & Co. from $52.00 to $54.00 in a report issued on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 22.42% from the stock’s current price.

Separately, Stifel Nicolaus decreased their price target on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a research note on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.17.

Qiagen Price Performance

Qiagen stock traded up $0.38 during trading hours on Tuesday, hitting $44.11. 126,539 shares of the stock were exchanged, compared to its average volume of 1,158,187. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84. The stock has a market capitalization of $10.07 billion, a P/E ratio of 29.58, a P/E/G ratio of 3.49 and a beta of 0.42. Qiagen has a 12 month low of $34.74 and a 12 month high of $47.70. The business’s 50-day moving average is $42.92 and its two-hundred day moving average is $43.64.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Monday, April 29th. The company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. The firm had revenue of $459.00 million for the quarter, compared to analysts’ expectations of $453.91 million. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.53 earnings per share. Equities research analysts expect that Qiagen will post 2.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Qiagen

Large investors have recently bought and sold shares of the business. Riverview Trust Co acquired a new position in Qiagen in the first quarter valued at approximately $28,000. Tower Research Capital LLC TRC raised its holdings in Qiagen by 66.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock worth $31,000 after purchasing an additional 283 shares during the period. Park Place Capital Corp acquired a new stake in Qiagen in the first quarter worth $36,000. Quarry LP acquired a new stake in Qiagen in the fourth quarter worth $38,000. Finally, Toronto Dominion Bank acquired a new stake in Qiagen in the third quarter worth $41,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.